<DOC>
	<DOCNO>NCT01334918</DOCNO>
	<brief_summary>The purpose study compare Multidetector Computed Tomography ( MDCT ) Single Photon Emission Computed Tomography ( SPECT ) stress myocardial perfusion imaging ( MPI ) regadenoson order detect presence absence reversible defect .</brief_summary>
	<brief_title>A Study Regadenoson Subjects Undergoing Stress Myocardial Perfusion Imaging ( MPI ) Using Multidetector Computed Tomography ( MDCT ) Compared Single Photon Emission Computed Tomography ( SPECT )</brief_title>
	<detailed_description>All participant randomize one two imaging sequence : rest/stress SPECT Day 1 follow stress/rest MDCT Day 2 stress/rest MDCT Day 1 follow rest/stress SPECT Day 2 . All stress scan involve injection regadenoson pharmacologic stress agent .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
	<criteria>Male subject must ≥ 45 year age Female subject must ≥ 50 year age Subject meet least one follow three criterion : suspect ( clinical impression ) know diagnosis coronary artery disease ( CAD ) typical angina refer nuclear cardiology lab schedule cardiac compute tomography ( CT ) schedule stable symptom possible elective catheterization procedure schedule imaging may beneficial ; know CAD previous invasive coronary angiography ( ICA ) perform 12 week prior screen present new cardiac symptom Subject refer clinically indicate myocardial perfusion image procedure Cardiac CT procedure suspect moderate high risk CAD Subject must abstain eat drink 30 minute prior 30 minute post study drug administration Subject must abstain smoke 3 hour prior 8 hour post study drug administration Subject must abstain intake methylxanthinecontaining food beverage within 12 hour prior Day 1 visit Day 3 FollowUp Visit , food may alter regadenoson effect . Subject able safely abstain theophylline use 12 hour prior study drug administration Subject concurrently participate another drug study receive investigational drug within 30 day prior Screening Subject history clinically significant illness ( CAD ) , medical condition , laboratory abnormality , would preclude participation study Subject renal dysfunction demonstrate glomerular filtration rate ( GFR ) &lt; 45 mL/min ( calculate use CockroftGault formula Note : Subjects GFR 4560 mL/min undergo hydration procedure Female subject pregnant , lactate childbearing potential refuse use medically acceptable form contraception Telephone Follow Visit complete Female subject positive pregnancy test prior randomization Subject history second third degree heart block sinus node dysfunction unless subject function pacemaker Subject symptomatic hypotension ( temporary reversible condition longer exist allow ) Subject allergic intolerant aminophylline , nitroglycerin metoprolol Subject allergic intolerant regadenoson excipients Subject unable unwilling comply procedure schedule Subject previously enrol study enrol another regadenoson study sponsor Astellas Subject atrial fibrillation significant arrhythmia may result decreased image quality image study ( CT SPECT ) Subject high heart rate ( &gt; 65 beat per minute ) contraindication administer betablockers ( severe chronic obstructive pulmonary disease ( COPD ) asthma , second third degree atrioventricular block )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Coronary Artery Disease ( CAD )</keyword>
	<keyword>ischemia</keyword>
	<keyword>pharmacologic stress</keyword>
	<keyword>regadenoson</keyword>
</DOC>